Xiamen Humanity Hospital
Ovarian cancer treatment cost in China typically includes diagnostics like a PET-CT and primary procedures such as ovarian cancer surgery which runs $17,500 to $33,500. Other options like chemotherapy for ovarian cancer range from $22,000 to $48,000. Total expenses depend on the cancer stage and hospital type. Patients often find 40-70% savings compared to the US. Top cities for treatment include Guangzhou and Xiamen.
Typical Ovarian Cancer Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients find significant value at JCI-accredited centers like Fuda Cancer Hospital. This facility specializes in late-stage cases using NanoKnife and cryosurgery technologies. For precision radiation, Xiamen Humanity Hospital is optimal due to Professor Liu Shi Xin's expertise. These specialized centers offer integrated care that often reduces the need for multiple hospital transfers.
| China | Turkey | Austria | |
| Оophorectomy | from $7,800 | from $2,500 | from $15,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $3,250 | from $12,000 |
| Ovarian cancer surgery | from $17,500 | from $4,800 | from $25,000 |
| Omentectomy | from $6,500 | from $5,760 | from $15,000 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $22,500 | from $6,500 | from $40,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Ovarian cancer treatment in China integrates cytoreductive surgery with platinum-based chemotherapy and maintenance therapies. Specialized centers combine Western protocols with Traditional Chinese Medicine to manage side effects. Advanced options like HIPEC, CyberKnife M6 radiosurgery, and Natural Killer cell therapy are available for complex or recurrent cases.
Bookimed Expert Insight: China is a global leader in combining traditional hospital stays with high-tech outpatient oncology. A package at Jinshazhou Hospital of Guangzhou University of Chinese Medicine costs approximately $7,750 for CyberKnife M6. This includes transfers and medications but excludes hospital nights. This model allows patients to receive advanced radiation while staying in more comfortable local accommodations.
Patient Consensus: Patients emphasize the importance of early genetic testing for BRCA status to access targeted therapies. Many note that high-volume hospitals in Guangzhou offer shorter wait times than public facilities in other regions.
Innovative maintenance therapies for ovarian cancer in China focus on targeted agents and cellular treatments. These include PARP inhibitors like olaparib and niraparib to repair DNA gaps. Anti-angiogenesis inhibitors and novel immunotherapies, including NK cell therapy, are also used within JCI-accredited facilities.
Bookimed Expert Insight: Genetic testing for BRCA and HRD markers is essential before selecting maintenance protocols. Chinese-manufactured PARP inhibitors offer similar efficacy to international brands at approximately 30% of the cost. Patients should verify if their package includes genomic profiling to ensure the therapy fits their profile.
Patient Consensus: Patients highlight that starting maintenance post-chemotherapy and managing fatigue are vital for long-term health. Many emphasize tracking CA-125 levels monthly to adjust therapy quickly if indicators change.
China offers advanced minimally invasive treatments for ovarian cancer, including NanoKnife (irreversible electroporation), cryosurgery, and microwave hyperthermal therapy. Specialized centers utilize CyberKnife M6 radiosurgery and DaVinci robotic systems for precise tumor removal. These ablative techniques target diseased tissue while preserving healthy surrounding organs.
Bookimed Expert Insight: While many countries focus on traditional debulking, Chinese JCI-accredited facilities like Fuda Cancer Hospital specialize in combining multiple minimally invasive therapies. Our data shows these centers often treat late-stage cases using a `3C` approach: cryosurgery, cancer microvascular intervention, and combined immunotherapy. This multimodal strategy is aimed at patients who are not candidates for conventional open surgery.
Patient Consensus: Patients note that while recovery from these ablative procedures is often faster than traditional surgery, it is vital to confirm long-term data. Some emphasize that these `miracle` options require careful screening to ensure they suit specific cancer stages.
The 5-year survival rate for ovarian cancer in China is approximately 43.7% in top centers. This baseline varies by cancer stage and patient age. Pediatric and adolescent cases show higher survival reaching 77.2%. Urban oncology centers consistently report better outcomes than rural facilities.
Bookimed Expert Insight: Patient volume is a major indicator of quality in Chinese oncology. Fuda Cancer Hospital serves over 30,000 patients from 100 countries. This high volume allows surgeons to master specific skills like cryosurgery. A CyberKnife M6 package from Jinshazhou Hospital costs approximately $7,750 (56,000 CNY). These bundles often include VIP transfers and doctor consultations which streamline complex medical travel.
Patient Consensus: Patients note that arriving at a specialized center quickly is vital for success. Many travelers recommend verifying a surgeon's specific volume in procedures like debulking before starting treatment.
International patients should plan to stay in China for 2 to 4 weeks after ovarian cancer surgery. This duration ensures initial wound stability and proper recovery. Most patients require 5 to 10 days of hospitalization. A further 14 days of local monitoring helps prevent complications for long-haul travel.
Bookimed Expert Insight: JCI-accredited facilities like Fuda Cancer Hospital focus on minimally invasive therapies that often reduce recovery times. While standard surgery requires a long stay, CyberKnife M6 packages available in Guangzhou include hotel stays and transfers. This coordination helps patients manage the transition from clinical care to travel readiness without logistical delays.
Patient Consensus: Patients note that hospitals may discharge you within 10 days. They emphasize booking a hotel nearby for another 2 weeks to handle follow-up care and pain management before flying home.
Medical tourism treatment packages bundle clinical procedures with essential travel logistics. They typically include surgery or radiosurgery, professional medical fees, and hospital facility charges. Most comprehensive options also provide ground transportation, bilingual coordination, and local accommodation to ensure a seamless healthcare experience.
Bookimed Expert Insight: China's leading oncology centers often prioritize specialized technology over standard hotel inclusions. For example, Jinshazhou Hospital offers advanced CyberKnife M6 radiosurgery with clinic transfers. However, their 56,000 CNY (approximately $7,850) oncology packages may not include hotel nights. Always check if accommodation is bundled or offered as an add-on.
Patient Consensus: Patients note it is important to budget extra for unexpected scans or extended recovery days. Many suggest getting all inclusions in writing to avoid surprises after arrival.
Identifying a high-quality cancer hospital in China requires selecting Grade 3-A institutions or JCI-accredited centers in medical hubs like Guangzhou, Beijing, or Shanghai. Prioritize facilities specializing in advanced oncology services, including robotic surgery, HIPEC, and minimally invasive treatments like cryosurgery or NanoKnife.
Bookimed Expert Insight: While public Tier-1 hospitals are excellent, international patients often face long admission waitlists. Data shows JCI-accredited facilities in Guangzhou, like Fuda Cancer Hospital, cater specifically to global arrivals with dedicated coordination. Choosing a clinic that offers bundled packages, such as Jinshazhou Hospital’s CyberKnife program for approximately $7,800, often includes necessary transfers and hotel stays that public hospitals rarely provide.
Patient Consensus: Patients emphasize choosing top-tier public hospitals in major cities to avoid quality variations. Many suggest hiring a personal translator for smoother navigation even within international departments.